US Patent 6,559,183: Scope, Claims, Expiration and ALA Photodynamic Therapy Patent Landscape

US Patent 6,559,183 covers 5-aminolevulinic acid, or ALA, nanoemulsions using a lipid carrier and an emulsifier that includes soybean lecithin. Its claim set also reaches topical pharmaceutical formulations, stable gel and lotion compositions, preparation processes, photodynamic therapy, treatment of proliferative diseases, and detection of proliferating cells. The patent term has expired, so the principal current risk is not direct enforcement of US 6,559,183 but the existence of later, unexpired patents covering specific ALA formulations, manufacturing controls, devices, or treatment protocols.

What does US Patent 6,559,183 protect?

The patent protects a combination of formulation, process, therapeutic-use and diagnostic claims.

Claim group	Claims	Principal subject matter	Required technical elements
Core composition	1-4, 8-9	ALA-containing nanoemulsion	ALA or specified derivative; aqueous phase; lipid carrier; emulsifier comprising soybean lecithin
Particle size and concentration	2-3	Formulation parameters	10-200 nm particles; 1-25 wt% active substance
Gel and lotion formulations	5-6	Defined dosage-form compositions	Specified ALA, carrier, adjuvant and water ranges
Stability	7	Storage-stable formulation	Active-substance loss of no more than 5% after one year at room temperature
Kit	10	Topical PDT kit	Composition plus light-impermeable covering, attachment means or applicator
Manufacturing	11-13	Nanoemulsion production	Carrier and aqueous phase converted to nanoemulsion; ALA added before or after emulsification; optional exclusion of oxygen/light; 5-45°C
Photodynamic therapy	14-19	Treatment methods	Topical or systemic administration, incubation and irradiation
Disease indications	15-18	Proliferative disorders	Tumors, basal-cell carcinoma, squamous-cell carcinoma, Bowen's disease, solar keratosis, condylomata, VIN, nodose or subcutaneous cancer and psoriasis
Detection	20-21	Cell-proliferation detection	Selective concentration of a metabolically produced photosensitizer in proliferating cells

The independent composition claim is the commercial center of gravity. It requires more than ALA and a topical vehicle. A potentially infringing product must contain a nanoemulsion in which the carrier has at least one lipid and at least one emulsifier comprising soybean lecithin.

What are the key limitations of claim 1?

Claim 1 is broad in the choice of active substance but narrower in the required delivery system.

Active substance requirement

The claim covers:

5-aminolevulinic acid;
salts of ALA;
complexes and addition compounds;
precursors; and
metabolites,

provided that the substance can be converted into protoporphyrin IX.

This language is designed to capture ALA hydrochloride and related ALA forms used to generate protoporphyrin IX in tissue. It does not automatically cover every photosensitizer or every topical photodynamic therapy product. A compound must fall within the claimed conversion and substance categories.

Nanoemulsion requirement

The formulation must be a nanoemulsion. A conventional cream, ointment, solution, suspension or ordinary emulsion would not satisfy this limitation unless its structure and particle characteristics meet the legal and technical meaning of nanoemulsion.

Claim 2 narrows the particle-size range to 10-200 nm. Claim 1 itself does not provide an express numerical particle-size limitation. A product can therefore raise a claim-construction issue if it is marketed as a microemulsion, submicron emulsion or lipid dispersion rather than a nanoemulsion.

Soybean lecithin requirement

The emulsifier must comprise soybean lecithin. This is a critical design-around limitation. A formulation using a different phospholipid or non-soy emulsifier may avoid literal infringement of claim 1, subject to the doctrine of equivalents and the scope of later patents.

The claim does not require soybean lecithin to be the only emulsifier, the predominant emulsifier or a particular percentage of the composition. It requires an emulsifier comprising soybean lecithin.

Lipid-carrier requirement

The carrier must be formed from at least one lipid. The claim therefore reaches lipid-based aqueous nanoemulsions, not all aqueous ALA formulations.

A formulation containing soybean lecithin as an excipient but lacking the claimed lipid-carrier architecture presents a stronger non-infringement position than a formulation with a defined phospholipid nanoemulsion system.

How do claims 2 through 9 affect product coverage?

Claims 2 through 9 add commercial formulation characteristics, but they do not replace the limitations of claim 1.

Particle size: claim 2

Claim 2 covers an average emulsified-particle size of 10-200 nm. This range is commercially significant because it encompasses many pharmaceutical nanoemulsions while excluding larger conventional emulsions.

Particle-size testing would need to address:

the measurement technique;
the sampling protocol;
whether the relevant value is number-average, volume-average or intensity-weighted;
formulation dilution during testing; and
whether the result changes during storage.

A product outside 10-200 nm may avoid claim 2 while remaining within claim 1 if it is otherwise a nanoemulsion.

Active concentration: claim 3

Claim 3 covers 1-25 wt% active substance. The range is broad enough to include the 10% ALA concentration used in commercial topical PDT products.

The calculation depends on how the active substance is measured. ALA free base, ALA hydrochloride and a formulated salt may produce different weight percentages depending on whether the calculation uses the salt or ALA-equivalent content.

Gel and lotion claims: claims 5 and 6

Claim 5 requires a gel containing:

5-15% active substance;
45-55% carrier;
1-5% adjuvants; and
water as the remainder.

Claim 6 requires a lotion containing:

5-15% active substance;
15-25% carrier;
15-25% adjuvants; and
water as the remainder.

These are composition-range claims. A commercial formulation must satisfy the full set of percentage limitations to infringe the relevant dependent claim. A product that contains 10% ALA but uses 30% carrier and 10% adjuvants would not meet claims 5 or 6, although it could still implicate claim 1 or another patent.

Claim 7 imposes a functional stability limitation: no more than 5% reduction in active substance after one year at room temperature. This limitation may require stability data and raises issues concerning the starting assay, storage container, temperature definition and analytical method.

What do the manufacturing claims cover?

Claims 11-13 protect a process in which a mixture of carrier and aqueous phase is converted into a nanoemulsion, with the active substance added before or after nanoemulsion formation.

The process claims cover two sequencing options:

ALA is added before the nanoemulsion is formed.
ALA is added after the nanoemulsion is formed.

Claim 12 adds exclusion of oxygen and/or light. Claim 13 limits the process temperature to 5-45°C.

The process claims are potentially relevant to contract manufacturers because they focus on manufacturing steps rather than the commercial label. A manufacturer could avoid literal infringement of claim 13 by operating outside the claimed temperature range, but the process would still need to be assessed against other patent claims and the doctrine of equivalents.

The exclusion of oxygen or light is an important process limitation. It may correspond to the known sensitivity of ALA-containing formulations and may be implemented through nitrogen blanketing, low-oxygen processing, opaque equipment or controlled lighting.

What medical uses are covered by claims 14 through 21?

Claims 14-19 cover photodynamic therapy using the claimed ALA nanoemulsion.

The basic sequence is:

Apply or administer the composition.
Incubate to allow tissue penetration and photosensitizer formation.
Irradiate the treated tissue with light.

The claims reach diseases associated with cell proliferation, including specified skin cancers and premalignant lesions. Claim 18 separately identifies psoriasis.

The method claims require use of the claimed composition. A photodynamic therapy method using ALA in a conventional solution or a different formulation may fall outside these claims, even if it uses the same light source and treatment sequence.

Claims 20 and 21 are diagnostic or research-use claims. They cover detecting proliferating cells by determining the extent to which a metabolically produced photosensitizer concentrates in proliferating cells compared with normal cells. These claims are materially different from the therapeutic claims and may implicate laboratory-use activity rather than commercial treatment.

When did US Patent 6,559,183 lose exclusivity?

US 6,559,183 is an issued US utility patent with a 20-year term measured from the applicable nonprovisional filing date, subject to any patent-term adjustment or other statutory modification. The patent family traces to a German priority filing and a US filing in 2001. On the ordinary term calculation, the patent expired in 2021.

Event	Timing
German priority filing	2000
US nonprovisional filing	2001
US patent grant	2003
Ordinary 20-year term endpoint	2021
Current enforceability	Expired

The patent is therefore no longer an enforceable US patent for ordinary infringement purposes. Patent expiration does not erase the patent's technical importance. Its claims remain relevant for freedom-to-operate history, prior-art analysis, prosecution strategy and assessment of later patents claiming improved versions of the same formulation concept.

What is the Orange Book status of the patent?

US 6,559,183 should not be treated as a current Orange Book barrier solely because it covers an ALA formulation used in a prescription product.

The FDA Orange Book lists patents submitted for approved drug products and accepted under FDA listing rules. A patent may be:

listed for an approved product;
excluded from listing;
removed after expiration;
retained as an expired historical entry; or
absent even though the patent relates technically to the product.

Ameluz, a 10% aminolevulinic acid hydrochloride gel marketed by Biofrontera, is the closest commercial product to the claimed formulation concept. The FDA-approved product is a topical ALA product for actinic keratoses. Levulan Kerastick, marketed by DUSA Pharmaceuticals, uses aminolevulinic acid hydrochloride but is a separate dosage form and delivery system.

The expiration of US 6,559,183 means it cannot independently block an ANDA launch today. A generic applicant would still need to evaluate currently unexpired Orange Book patents, regulatory exclusivity, labeling restrictions and other formulation or method-of-use patents.

Which companies compete in the ALA photodynamic therapy market?

Company	Product	Active substance	Delivery format	Relationship to US 6,559,183
Biofrontera	Ameluz	ALA hydrochloride	10% topical gel	Technically aligned with the patent's ALA nanoemulsion concept
DUSA Pharmaceuticals, a Sun Pharma company	Levulan Kerastick	ALA hydrochloride	Topically applied solution generated from a stick system	Different delivery system; does not necessarily require the claimed nanoemulsion
Generic developers	Potential ALA products	ALA or ALA hydrochloride	Solution, gel, cream or other topical format	6,559,183 is expired; later patents remain relevant

Ameluz is the stronger product-level reference point because its formulation uses a lipid/phospholipid-based system and was developed as a stable topical ALA gel. Levulan is a closer comparator for active ingredient and photodynamic use, but not necessarily for the claimed nanoemulsion architecture.

What Paragraph IV and generic-entry risks exist?

US 6,559,183 itself creates no current Paragraph IV risk because its term has expired. A Paragraph IV certification is relevant only to a patent listed for the reference drug and not yet expired.

For an ALA generic, the principal scenarios are:

Launch scenario	Likely legal posture
Same active ingredient, non-nanoemulsion solution	Lower risk under US 6,559,183; later patents must be checked
Same 10% ALA gel with soybean-lecithin nanoemulsion	Historical overlap with 6,559,183; current risk depends on later patents
Different emulsifier and carrier system	Stronger design-around position
Same formulation but different approved indication	Method-of-use and labeling-patent analysis required
Product relying on an abbreviated pathway	Orange Book certifications and exclusivity review required

A generic applicant could also pursue a formulation that avoids the soybean-lecithin limitation, uses a non-lipid vehicle, or does not meet the nanoemulsion definition. Those changes could affect stability, penetration, photodynamic efficacy and FDA comparability requirements.

How strong is the patent estate for ALA nanoemulsions?

US 6,559,183 had meaningful historical breadth because it combined:

a broad class of ALA-related actives;
a lipid nanoemulsion;
soybean lecithin;
topical pharmaceutical use;
defined gel and lotion embodiments;
manufacturing controls; and
PDT and diagnostic uses.

Its present exclusionary strength is zero because the US patent has expired. The remaining commercial value lies in later patents that may claim:

specific phospholipid ratios;
particular particle-size distributions;
stabilizer systems;
preservative combinations;
gel rheology;
packaging and light protection;
dosing schedules;
illumination parameters;
treatment of specific lesions;
manufacturing conditions; or
improved stability and penetration.

The original patent is therefore best classified as an expired foundational formulation patent, not a current blocking patent.

What licensing and litigation issues affect the patent?

The commercial history of ALA nanoemulsion products indicates that formulation technology, regulatory approvals and commercial rights have been important alongside patent ownership. Biofrontera developed and commercialized Ameluz, while DUSA/Sun Pharma commercialized Levulan. Product ownership, formulation licensing and patent ownership should be analyzed separately because the entity named as patent assignee may differ from the NDA holder or marketing company.

No current enforceable rights arise from US 6,559,183 after expiration. Any settlement, license or litigation based exclusively on this patent would have historical rather than prospective blocking significance. Current diligence should focus on later family members and separate patents identified in the relevant Orange Book entries and FDA regulatory records.

Key Takeaways

US 6,559,183 covers ALA-containing lipid nanoemulsions with an emulsifier comprising soybean lecithin.
Claim 1 is the core claim and requires the active substance, aqueous phase, lipid carrier, emulsifier and nanoemulsion architecture.
Claims 5 and 6 target defined gel and lotion compositions.
Claims 11-13 cover preparation processes, including optional oxygen/light exclusion and 5-45°C processing.
Claims 14-19 cover PDT treatment using the claimed formulation.
Claims 20-21 cover photosensitizer-based detection of proliferating cells.
The patent expired in 2021 under the ordinary 20-year US patent-term calculation.
It is not a current standalone barrier to generic entry.
Ameluz is the closest commercial formulation comparator; Levulan uses the same active-ingredient class but a different delivery format.
Current freedom-to-operate analysis must examine later patents, Orange Book listings and formulation-specific rights.

FAQs

Does US 6,559,183 cover all topical aminolevulinic acid products?

No. It requires a nanoemulsion with a lipid carrier and an emulsifier comprising soybean lecithin. A conventional ALA solution or non-lipid formulation may fall outside the claim.

Does the patent cover aminolevulinic acid hydrochloride?

Yes, the claim language covers salts of 5-aminolevulinic acid, which includes ALA hydrochloride, when used in the claimed nanoemulsion composition.

Can a generic avoid the patent by changing the particle size?

Changing particle size may avoid dependent claim 2, but it does not necessarily avoid claim 1. The product would still need to be assessed for whether it remains a nanoemulsion with the required lipid and soybean-lecithin components.

Is Ameluz blocked by US 6,559,183?

The patent historically covered formulation characteristics associated with Ameluz-type ALA nanoemulsions, but the patent expired in 2021. It is not a current enforceable barrier to Ameluz or an ALA generic.

Does the patent cover the light source used in photodynamic therapy?

No. The claims cover methods involving irradiation but do not, based on the supplied claims, claim a specific lamp, laser, wavelength, fluence or illumination device.

References

United States Patent No. 6,559,183. (2003). Nanoemulsion comprising 5-aminolevulinic acid. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2016). Ameluz (aminolevulinic acid hydrochloride) gel prescribing information. FDA.
U.S. Food and Drug Administration. (1999). Levulan Kerastick (aminolevulinic acid hydrochloride) prescribing information. FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
United States Patent and Trademark Office. (2024). Patent term calculator and patent term adjustment information. USPTO.
Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j). (1984). United States Code.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	198 52 245	Nov 12, 1998

PCT Information
PCT Filed	November 12, 1999	PCT Application Number:	PCT/EP99/08711
PCT Publication Date:	May 25, 2000	PCT Publication Number:	WO00/28971

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	260092	⤷ Start Trial
Australia	1271000	⤷ Start Trial
Australia	758098	⤷ Start Trial
Canada	2351620	⤷ Start Trial
Germany	19852245	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,559,183

Summary for Patent: 6,559,183